Adzynma is the first product to be approved for the treatment of the rare blood disorder that has 90% mortality when left untreated. Congenital thrombotic thrombocytopenic purpura (cTTP) can now be ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted Takeda’s Biologics License Application (BLA) ...

“Thrombotic Thrombocytopenic Purpura Market” The Thrombotic Thrombocytopenic Purpura market size is anticipated to grow due to pharmaceutical companies' extensive research and development activities ...

Thrombocytopenia is an atypically low platelet count. Acquired thrombocytopenia is caused by conditions that develop throughout your life instead of genes inherited from birth. Acquired ...

Thrombosis and thrombocytopenia have been reported after vaccination with the ChAdOx1 nCoV-19 vaccine (Oxford–AstraZeneca), a recombinant chimpanzee adenoviral vector encoding the spike glycoprotein ...

Thrombosis with thrombocytopenia syndrome happens when a person has both blood clots and low platelet counts after receiving certain COVID-19 vaccines. Thrombosis with thrombocytopenia syndrome (TTS) ...

Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of severe acute respiratory ...

Every time Marianne publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...

Please provide your email address to receive an email when new articles are posted on . Persistent low-to-moderate thrombocytopenia can identify patients with antiphospholipid syndrome who are at high ...

The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports linking these vaccines to immune thrombotic thrombocytopenic purpura (TTP).